These results expedited their approval by the US Food and Drug Administration for the treatment of locally advanced or metastatic NSCLC with KRAS-G12C mutations for patients who have received at least one prior systemic therapy. This evidence concerns the gene KRAS and non-small cell lung carcinoma.